|Articles|March 1, 2001

Pharmaceutical Executive

  • Pharmaceutical Executive-03-01-2001
  • Volume 0
  • Issue 0

Shortage: Vaccine Worries

United States-At this time last year, the United States} supply of tetanus vaccine was easily met by the two companies licensed to produce it there, Aventis Pasteur and Wyeth-Ayerst. But in June 2000, the latter ran into regulatory problems, and FDA seized thousands of substandard doses of acellular pertussis vaccine from the company}s Marietta, Pennsylvania, plant.

Articles in this issue

over 25 years ago

Research: New Horizons

over 25 years ago

Earnings: Tough Times Ahead

over 25 years ago

Outbreak: Anthrax Alarm

over 25 years ago

Patents: China on the Genome Map

over 25 years ago

Privacy, Pediatrics, and Policy

over 25 years ago

Lilly's International Family

over 25 years ago

Update: Punishment and Reprieve

over 25 years ago

Gateway to Japan

over 25 years ago

Surrounded

Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.